Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Cher

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Oncogene|December 14, 2011
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growthW Huang, Y Fridman, R D Bonfil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Systemic interleukin 2 therapy for human prostate tumors in a nude mouse modelJ A Triest, D J Grignon, M L Cher, et al.
The Journal of Urology|September 29, 1998
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomyM L Cher, F J Bianco, J S Lam, et al.
Cancer Research|July 1, 1996
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotypingM L Cher, G S Bova, D H Moore, et al.
Prostate Cancer and Prostatic Diseases|March 9, 2016
Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomyT M Morgan, S R Hawken, K R Ghani, et al.
The Journal of Biological Chemistry|September 22, 2000
Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2M Toth, M M Bernardo, D C Gervasi, et al.
Pathology Oncology Research : POR|March 1, 1996
Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterationsK V Honn, A Aref, Y Q Chen, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Oncogene|December 14, 2011
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growthW Huang, Y Fridman, R D Bonfil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Systemic interleukin 2 therapy for human prostate tumors in a nude mouse modelJ A Triest, D J Grignon, M L Cher, et al.
The Journal of Urology|September 29, 1998
Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomyM L Cher, F J Bianco, J S Lam, et al.
Cancer Research|July 1, 1996
Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotypingM L Cher, G S Bova, D H Moore, et al.
Prostate Cancer and Prostatic Diseases|March 9, 2016
Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomyT M Morgan, S R Hawken, K R Ghani, et al.
The Journal of Biological Chemistry|September 22, 2000
Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2M Toth, M M Bernardo, D C Gervasi, et al.
Pathology Oncology Research : POR|March 1, 1996
Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterationsK V Honn, A Aref, Y Q Chen, et al.
Pageof 4